Convalescent COVID-19 plasma
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease. December 31, 2019 marked the day the World Health Organization (WHO) first became aware of an infectious outbreak in the Hubei province in China. Until January 2021, more than two million people died from COVID-19. The use of convalescent plasma (CP) has been widely used in different outbreaks as the first therapeutic option given the lack of effective medications or vaccines, and often as a last chance or experimental treatment. CP is a strategy of passive immunisation. Possible mechanisms of CP-COVID-19 action are antiviral and immunomodulatory.
The established protocol for CP-COVID-19 collection defines activities and criteria related to recruiting and informing potential CP donors, clinical and laboratory examination, plasma collection, labelling and storage. Plasma is collected by apheresis/plasmapheresis. Administration of plasma is performed at the request of clinicians, according to the strict indications based on the severity of clinical picture, expressed by precisely determined “scoring” of symptoms. The risks transfusion recipients are likely to be exposed to do not differ from those of standard plasma recipients. At the Blood Transfusion Institute of Serbia, the first plasmapheresis from the recovered patient-donor was performed on 11 April 2020 and so far, collection and distribution of CP-COVID-19 have been performed continuously.
During the observation period, preliminary results of the effect of CP transfusion, along with other applied therapy, indicate its favourable effect, both worldwide and in Serbia. CP-COVID-19 should be used as early as possible in the course of infection in order to achieve the best outcomes.
References
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet, 2020;395: 497-506 doi:https://doi.org/10.1016/S0140-6736(20)30183-5
3. Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; May 20(5):533-534 doi: 10.1016/S1473-3099(20)30120-1.
4. Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow Transfus Clin Biol, 2016;23(1): 39-44 doi: 10.1016/j.tracli.2015.12.003.
5. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno G.M., et al .Convalescent plasma: New evidence for an old therapeutic tool?Blood Transfus, 2016;14: 152-157 Doi: 10.2450/2015.0131-15
6. Roback JD and Guarner J, Convalescent Plasma to Treat COVID-19: Possibilities and Challenges, JAMA 2020;323(16):1561–1562 doi:10.1001/jama.2020.4940.
7. Chen L, Xiong J, Bao L, Shi Y, Convalescent plasma as potential therapy for COVID-19. Lancet Infect Dis, 2020;20(4):398-400 doi: 10.1016/S1473-3099(20)30141-9.
8. Sean T. H. Liu, Hung-Mo Lin,Nicole M. Bouvier. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study Nat Med 2020; 26(11):1708–1713 doi: 10.1038/s41591-020-1088-9.
9. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications MedRxiv (2020), doi: https://doi.org/10.1101/2020.03.30.20047365
10. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy Immunol Rev. 1994;139:5-19 doi: 10.1111/j.1600-065x.1994.tb00854.
11. McGonagle D, Sharif K, O’Regan A, Bridgewood C.The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Autoimmun Rev 2020; 19(6): 102537 doi: 10.1016/j.autrev.2020.102537.
12. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al.Coagulopathy and antiphospholipid antibodies in patients with Covid-19 N Engl J Med, 2020; 382 (17) :e38 doi: 10.1056/NEJMc2007575.
13. Meffre E and Iwasaki A. Interferon deficiency can lead to severe COVID, Nature 2020;587(7834): 374-376 doi: 10.1038/d41586-020-03070-1.
14. European Committee on Blood Transfusion. Guide to the preparation, use and quality assurance of blood components. 20th ed. Strasbourg, France: European Directorate for the Quality of Medicines and HealthCare, 2020.
15. US FDA. Covid-19 Convalescent Plasma EUA decision memo. https://www.fda.gov/media/141480/download
16. WHO Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. Interim guidance. 10 July 2020.
17. Center for Biologics Evaluation and Research. Revised Information for Investigational COVID-19 Convalescent Plasma. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds Updated April 6, 2020. Accessed April 7, 2020.
18. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL.Deployment of convalescent plasma for the prevention and treatment of COVID-19 J.Clin Invest 2020;130(6):2757-2765 doi: 10.1172/JCI138745
19. Ling Li, Wei Zhang, Yu Hu, Xunliang Tong, et all Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Tria l JAMA. 2020; 324(5): 1–11. doi: 10.1001/jama.2020.10044.
20. Tanne J.H. Covid-19:FDA approves use of convalescent plasma to treat critically ill patients.BMJ.2020;368:m1256 doi: 10.1136/bmj.m1256.
21. Salazar E, Christensen P A,Graviss EA et all.Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decresed Mortality Am J Pathol. 2020; 190(11):2290-2303 2020 Nov; 190(11): 2290–2303.doi: 10.1016/j.ajpath.2020.08.001
22. Libster R, Perez Marc G, Wappner D. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults N Engl J Med 2021;384(7):610-618. doi: 10.1056/NEJMoa2033700
23. Joyner MJ, Wright R.S , Fairweather DeLisa et all. Early safety indicators of COVID-19 convalescent plasma in 5000 patients J Clin Invest 2020;130(9):4791-7. doi: 10.1172/JCI140200.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).